Drug Profile
Research programme: cell-cell fusion inhibiting peptides - Aplagen
Latest Information Update: 18 Mar 2011
Price :
$50
*
At a glance
- Originator AplaGen
- Class Peptides
- Mechanism of Action Cell adhesion molecule inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Multiple sclerosis
Most Recent Events
- 30 Jan 2007 Preclinical trials in Multiple sclerosis in Germany (Parenteral)